RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources-Reference-Cited by-同舟云学术

RAS testing and cetuximab treatment for metastatic colorectal cancer: a cost-effectiveness analysis in a setting with limited health resources

Published:2017-04-11 Issue:41 Volume:8 Page:71164-71172
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Wu Bin¹,Yao Yuan²,Zhang Ke³,Ma Xuezhen⁴

Affiliation:

1. Medical Decision and Economic Group, Department of Pharmacy, Ren Ji Hospital, South Campus, School of Medicine, Shanghai Jiaotong University, Shanghai, P.R. China

2. Department of Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China

3. Department of Medical Oncology, Qingdao Commercial Worker‘s Hospital, Qingdao, Shandong, P.R. China

4. Department of Medical Oncology, Qingdao Central Hospital, The Second Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, P.R. China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation on the cost–effectiveness of Cetuximab in treatment of colorectal cancer: a systematic review;Colorectal Cancer;2024-08-27

2. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

3. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment for mismatch-repair-deficient (dMMR) or microsatellite-instability-high (MSI-H) advanced or metastatic colorectal cancer from the perspective of the Chinese health-care system;BMC Health Services Research;2023-10-11

4. Pembrolizumab alone or in combination with chemotherapy versus chemotherapy for advanced gastric cancer: A cost‐effectiveness analysis;Cancer Medicine;2023-09

5. Cost-effectiveness analysis of axicabtagene ciloleucel as a second-line treatment for diffuse large B-cell lymphoma in China and the United States;Therapeutic Advances in Hematology;2023-01